Dana-Farber’s Breast Oncology Center

Oncologist Near Me - Paolo Tarantino (@PTarantinoMD): Shaping the Future of Breast Cancer Treatment @DanaFarber @harvardmed oncodaily.com/oncolibrary/on… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #OncologistNearMe #BreastCancer #DanaFarber…

Honored to join the @myESMO Young Oncologists Committee! Grateful for the opportunity to contribute and help support the next generation of YOCs through education, mentorship, and global collaboration. Excited for what’s ahead!

Check out this podcast where @DanaFarber's Sara Tolaney, MD, MPH discusses how the results from the DESTINY-Breast09 study are redefining first-line treatment in HER2-positive #MetastaticBreastCancer. She explores whether #TDXd plus #pertuzumab should replace the long-standing…

We’re proud to be included in @Newsweek’s America’s Greatest Workplaces by State 2025 list. This recognition reflects our ongoing commitment to fostering a supportive, inclusive, and mission-driven workplace – one where every team member has the opportunity to thrive and grow.…

Regular exercise isn’t just great for fitness. It can also reduce cancer risk by managing weight, improving immunity, and lowering inflammation.

Check out this npj Breast Cancer review: Unveiling the paradigm shift: Systemic treatment strategies in small, node-negative #BreastCancer 🔓pubmed.ncbi.nlm.nih.gov/40379683/ @marianascarant1 @renata_bonadio @DrRBarroso

The FDA granted breakthrough therapy designation to first-line treatment with trastuzumab deruxtecan (Enhertu) plus pertuzumab (Perjeta) for unresectable or metastatic HER2+ #BreastCancer. Check out this @cure_today interview where Dr. Sara Tolaney (@stolaney1) discusses the…

Hi friends, it's #BreastCancer Tuesday. Here are Top Posts of the Week! 🎉🎉🎉 1/ @stolaney1 on managing the axilla after preop tx: x.com/stolaney1/stat…

Mark your calendars for PER’s School of Breast Oncology (SOBO), November 6-8, 2025! Register for FREE using my last name (TOLANEY) as a discount code! I always learn so much from this incredible course! #gotoPER #SOBO25 gotoper.com/courses/school…

Join @DanaFarber's Paolo Tarantino, MD (@PTarantinoMD) at the free, virtual EMBRACE Patient Forum for updates on treatment and research on #MetastaticBreastCancer presented at #ASCO25. A Q&A moderated by Sarah Sammons, MD (@drsarahsam) will follow! 🗓️July 30, 2025 | 1 – 2 pm ET…

Combining ADCs: the future is now. (Though it will require more payload differentiation…!)

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis buff.ly/1loYQqK A comprehensive individual patient-level meta-analysis of over 2,500 patients from 11 studies demonstrated that the HER2DX genomic test…

Check out the fiercest breast onc debate of 2025: should ADCs be sequenced? 🥊 @laura_huppert

New research suggests #exercise may play a more significant role in cancer treatment than we thought, but is it safe for #HER2-positive breast cancer patients? Learn more in our Q&A with Dr. Jennifer Ligibel 👉 bit.ly/4eQDQv4 #cancercare #digitalhealth

After CDK4/6 Inhibitors: Advancing Treatment for HR+HER2-negative Metastatic Breast Cancer— Mafalda Oliveira, Erica Mayer, and Shom Goel will address this topic in an educational session at #SABCS25 (December 9-12). brnw.ch/21wUjob @MOliveira_MD @elmayermd @shomgoel

@DFCI_BreastOnc is leading the ADEPT study, examining the non-chemotherapy combination of HER2-directed therapy (trastuzumab and pertuzumab) + hormonal therapy as a treatment after surgery for early HR+/HER2+ #BreastCancer. Call 877-338-7425 or visit:​ dana-farber.org/clinical-trial…

Check out this session from our CME Symposium Series in conjunction with the 2025 ASCO® Annual Meeting about the current and future clinical care of patients with HER2-positive gastrointestinal cancers. ow.ly/Ul8R50Wo111

Combining ADCs has shown a potential improvement in survival, but it may also come with increased toxicities. #bcsm | @PTarantinoMD cancernetwork.com/view/assessing…